Thomas R. Cannell
2021 - Eleven Biotherapeutics
In 2021, Thomas R. Cannell earned a total compensation of $4.9M as President and Chief Executive Officer at Eleven Biotherapeutics, a 189% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $236,250 |
---|---|
Option Awards | $4,123,086 |
Salary | $558,362 |
Other | $4,000 |
Total | $4,921,698 |
Cannell received $4.1M in option awards, accounting for 84% of the total pay in 2021.
Cannell also received $236.3K in non-equity incentive plan, $558.4K in salary and $4K in other compensation.
Rankings
In 2021, Thomas R. Cannell's compensation ranked 2,674th out of 12,415 executives tracked by ExecPay. In other words, Cannell earned more than 78.5% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 2,674 out of 12,415 | 79th |
Division Manufacturing | 1,052 out of 5,508 | 81st |
Major group Chemicals And Allied Products | 412 out of 2,378 | 83rd |
Industry group Drugs | 359 out of 2,099 | 83rd |
Industry Pharmaceutical Preparations | 236 out of 1,549 | 85th |
Source: SEC filing on April 28, 2022.
Cannell's colleagues
We found two more compensation records of executives who worked with Thomas R. Cannell at Eleven Biotherapeutics in 2021.
News
Eleven Biotherapeutics CEO Steven Kelly receives $3.5M in 2023
April 29, 2024
Eleven Biotherapeutics CEO Thomas Cannell's 2022 pay falls 72% to $1.4M
April 28, 2023
Eleven Biotherapeutics CEO Thomas Cannell's 2021 pay jumps 189% to $4.9M
April 28, 2022
Eleven Biotherapeutics CEO Thomas Cannell's 2020 pay jumps 21% to $1.7M
March 25, 2021
Eleven Biotherapeutics CEO Thomas Cannell's 2019 pay falls 30% to $1.4M
March 30, 2020
Eleven Biotherapeutics CEO Thomas Cannell receives $2M in 2018
April 30, 2019